sofnobrutinib

Sofnobrutinib (AS-0871) is a highly selective, orally available, non-covalent inhibitor of Bruton's tyrosine kinase (BTK) being developed by Carna Biosciences for the treatment of inflammatory and immune disorders. Unlike many first-generation BTK inhibitors that bind covalently, sofnobrutinib is designed to bind preferentially to the non-activated form of the BTK protein, a mechanism intended to achieve extreme selectivity and minimize off-target side effects. BTK is a critical mediator in B-cell antigen receptor (BCR) signaling and Fcε receptor signaling in mast cells and basophils, making it a key target for autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus, as well as allergic conditions. Sofnobrutinib has completed Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trials in healthy volunteers, where it demonstrated a favorable safety profile and dose-dependent suppression of basophil and B-cell activation.